| Company Name: |
Biolab Reagents |
| Tel: |
027-65279366 18108604356 |
| Email: |
products@biolabreagent.com |
|
| | Zuberitamab Basic information |
| Product Name: | Zuberitamab | | Synonyms: | Zuberitamab;Research Grade Zuberitamab (DHC90719);Research Grade Zuberitamab | | CAS: | 2251143-19-6 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Zuberitamab Structure]() |
| | Zuberitamab Chemical Properties |
| | Zuberitamab Usage And Synthesis |
| Uses | Zuberitamab (HS006) is a monoclonal antibody that targets CD20 and can be used in cancer research, including diffuse large B-cell lymphoma[1]. | | in vivo | Zuberitamab (0.1mg/kg, intravenous injection, on day 0 and 10, 2 weeks) alone has no or minimal effect on tumor growth, when combined with BR105 results in significant inhibition of tumor growth with good anti-tumor efficacy in IRPα-humanized B-NDG mice tumor xenograft model[1].
| | References | [1] Zhen-Hua Wu, et al. Preclinical characterization of the novel anti-SIRPα antibody BR105 that targets the myeloid immune checkpoint. J Immunother Cancer. 2022 Mar;10(3):e004054. DOI:10.1136/jitc-2021-004054 |
| | Zuberitamab Preparation Products And Raw materials |
|